1. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival
Neuroendocrinology 2017;104: DOI: /
Fig. 1. Overall survival in the whole cohort of 85 patients included into the PROMID study according to treatment (conservative intention-to-treat analysis).
© 2016 S. Karger AG, Basel

2. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival
Neuroendocrinology 2017;104: DOI: /
Fig. 2. Overall survival in the whole cohort of 85 patients included into the PROMID study according to hepatic tumor load (conservative intention-to-treat analysis).
© 2016 S. Karger AG, Basel

3. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival
Neuroendocrinology 2017;104: DOI: /
Fig. 3. Overall survival in the subgroup of 64 patients with a hepatic tumor load ≤10% according to treatment (conservative intention-to-treat analysis).
© 2016 S. Karger AG, Basel